Ventricular fibrillation medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(21 intermediate revisions by 4 users not shown)
Line 2: Line 2:
{{Ventricular fibrillation}}
{{Ventricular fibrillation}}
{{CMG}}
{{CMG}}
==Overview==
==Overview==
In the event of [[cardiac arrest]] due to ventricular fibrillation, the immediate implementation of [[ACLS]] guidelines is indicated. When a [[sudden cardiac arrest]] occurs, immediate [[CPR]] is a vital link in the [[chain of survival]]. Another important link is early [[defibrillation]], which has improved greatly with the widespread availability of [[Automated external defibrillator|AED]]s. It often starts with analysing patient's [[Heart rhythm|heart rhythms]] with a manual [[defibrillator]].
==Medical Therapy==
==Medical Therapy==
===Defibrillation===
===Defibrillation===
====Electric defibrillator====
====Electric Defibrillator====
The condition can often be reversed by the electric discharge of [[direct current]] from a [[defibrillator]]. Although a defibrillator is designed to correct the problem, and its effects can be dramatic, it is not always successful.
The [[condition]] can often be reversed by the electric discharge of [[direct current]] from a [[defibrillator]]. Although a [[defibrillator]] is designed to correct the problem, and its effects can be dramatic, it is not always successful.
=====Implantable Electric Defibrillator=====
In [[patients]] at high risk of ventricular fibrillation, the use of an
[[Implantable cardioverter-defibrillator|implantable cardioverter defibrillator]] has been shown to be beneficial.
====Precordial Thump====
If no [[defibrillator]] is available, a [[precordial thump]] can be delivered at the onset of VF for a small chance to regain cardiac function. However, research has shown that the precordial thump releases no more than 30 [[joule]]s of energy. This is far less than the 200–360 J typically used to bring about normal [[sinus rhythm]]. Consequently, in the hospital setting, this treatment is not used.


=====Implantable electric defibrillator=====
===Antiarrhythmic Agents===
In patients at high risk of ventricular fibrillation, the use of an
[[Antiarrhythmic agents]] like [[amiodarone]] or [[lidocaine]] can help, but, unlike [[atrial fibrillation]], ventricular fibrillation rarely reverses spontaneously in large adult mammals. Drug therapy with antiarrhythmic agents in ventricular fibrillation does not replace [[defibrillation]] and is not the first priority, but is sometimes needed in cases where initial [[defibrillation]] attempts are not successful.
[[Implantable cardioverter-defibrillator|implantable cardioverter defibrillator]] has been shown to be beneficial.


====Precordial thump====
[[Medications]] that may be used include:
If no defibrillator is available, a [[precordial thump]] can be delivered at the onset of VF for a small chance to regain cardiac function. However, research has shown that the precordial thump releases no more than 30 [[joule]]s of energy{{Citation needed|date=March 2009}}. This is far less than the 200–360 J typically used to bring about normal sinus rhythm. Consequently, in the hospital setting, this treatment is not used.
*[[Amiodarone]], 300 mg bolus IV for VF/[[pulseless VT]] arrest and then 1 mg/min for 6 h.
** Common [[side effects]] include [[hypotension]], [[bradycardia]], [[atrioventricular block]], [[Torsade de pointes|Torsade de point]], [[corneal]] microdeposits, [[thyroid]] abnormalities, and [[pulmonary fibrosis]].
*[[Lidocaine]], 1 mg/kg bolus IV and then 1–3 mg/min 1–1.5 mg/kg.  
** Common [[side effects]] include [[bradycardia]], hemodynamic collapse, [[atrioventricular block]], and [[sinus arrest]].
*[[Quinidine]], 800 mg in 50 mL IV infused at 50 mg/min.
** Common [[side effects]] include [[syncope]], [[Torsade de pointes|Torsade de point]], [[atrioventricular block]].
*[[Sotalol]], 75 mg IV.
** Common [[side effects]] include [[bradycardia]], [[hypotension]], [[heart failure]], and [[syncope]].
====Contraindicated medications====
{{MedCondContrAbs|MedCond = Ventricular fibrillatioins|Digoxin|Diltiazem|Calcium chloride|Calcium gluconate}}


===Antiarrhythmic agents===
==2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death<ref name="Al-KhatibStevenson2018">{{cite journal|last1=Al-Khatib|first1=Sana M.|last2=Stevenson|first2=William G.|last3=Ackerman|first3=Michael J.|last4=Bryant|first4=William J.|last5=Callans|first5=David J.|last6=Curtis|first6=Anne B.|last7=Deal|first7=Barbara J.|last8=Dickfeld|first8=Timm|last9=Field|first9=Michael E.|last10=Fonarow|first10=Gregg C.|last11=Gillis|first11=Anne M.|last12=Granger|first12=Christopher B.|last13=Hammill|first13=Stephen C.|last14=Hlatky|first14=Mark A.|last15=Joglar|first15=José A.|last16=Kay|first16=G. Neal|last17=Matlock|first17=Daniel D.|last18=Myerburg|first18=Robert J.|last19=Page|first19=Richard L.|title=2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death|journal=Circulation|volume=138|issue=13|year=2018|issn=0009-7322|doi=10.1161/CIR.0000000000000549}}</ref>==
[[Antiarrhythmic agents]] like [[amiodarone]] or [[lidocaine]] can help, but, unlike [[atrial fibrillation]], ventricular fibrillation rarely reverses spontaneously in large adult mammals. Drug therapy with antiarrhythmic agents in ventricular fibrillation does not replace [[defibrillation]] and is not the first priority, but is sometimes needed in cases where initial defibrillation attempts are not successful.
===Acute Management of Ventricular Fibrillation===
{|class="wikitable"
|-
| colspan="1" style="text-align:center; background:LightGreen"|[[AHA guidelines classification scheme#Classification of Recommendations|Class I]]
|-
|bgcolor="LightGreen" |<nowiki>"</nowiki>'' In [[patients]] with hemodynamically unstable VA that persist or recur after a maximal energy shock, intravenous [[amiodarone]] should be administered to attempt to achieve a stable [[rhythm]] after further [[defbrillation]]. ([[AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])''<nowiki>"</nowiki>
|}
{|class="wikitable"
|-
| colspan="1" style="text-align:center; background:LemonChiffon"|[[AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]
|-
|bgcolor="LemonChiffon" |<nowiki>"</nowiki>''In [[patients]] with symptomatic, non–lifethreatening VA, treatment with a [[beta blocker]] is reasonable. ([[AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki>
|}
{|class="wikitable"
|-
| colspan="1" style="text-align:center; background:LemonChiffon"|[[AHA guidelines classification scheme#Classification of Recommendations|Class IIb]]
|-
|bgcolor="LemonChiffon" |<nowiki>"</nowiki>''In [[patients]] with VT/VF storm in whom a [[beta blocker]], other antiarrhythmic [[medications]], and catheter ablation are ineffective, not tolerated, or not possible, [[cardiac]] sympathetic denervation may be reasonable.([[AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki>
|}
===Ventricular Fibrillation in Specific Conditions===
{|class="wikitable"
|-
| colspan="1" style="text-align:center; background:LightGreen"|[[AHA guidelines classification scheme#Classification of Recommendations|Class I]]
|-
|bgcolor="LightGreen" |<nowiki>"</nowiki>''In [[patients]] with polymorphic [[VT]] or VF with ST-elevation [[MI]], [[angiography]] with emergency revascularization is recommended. ([[AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki>
|}
{|class="wikitable"
|-
| colspan="1" style="text-align:center; background:LemonChiffon"|[[AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]
|-
|bgcolor="LemonChiffon" |<nowiki>"</nowiki>''In [[patients]] with a witnessed cardiac arrest due to VF or polymorphic VT that is unresponsive to [[CPR]], [[defbrillation]], and vasopressor therapy, intravenous [[lidocaine]] can be benefcial.([[AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki>
|-
|bgcolor="LemonChiffon" |<nowiki>"</nowiki>''In [[patients]] with a recent [[MI]] who have VT/VF that repeatedly recurs despite direct current cardioversion and antiarrhythmic [[medications]] (VT/VF storm), an intravenous [[beta blocker]] can be useful.([[AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki>
|}
{|class="wikitable"
|-
|colspan="1" style="text-align:center; background:LightCoral"| [[AHA guidelines classification scheme#Classification of Recommendations|Class III]] (No Benefit)
|-
|bgcolor="LightCoral"|<nowiki>"</nowiki> In [[patients]] with refractory VF not related to [[torsades de pointes]], administration of intravenous [[magnesium]] is not benefcial.''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki>
|-
|bgcolor="LightCoral"|<nowiki>"</nowiki>In [[patients]] with incessant VT or VF, an ICD should not be implanted until suffcient control of the VA is achieved to prevent repeated ICD shocks. ''([[AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki>
|}


==References==
==References==
{{reflist|2}}
{{reflist|2}}
 
[[Category:Cardiology]]
[[Category:Up-To-Date cardiology]]
[[Category:Up-To-Date]]
[[Category:Electrophysiology]]
[[Category:Emergency medicine]]
[[Category:Intensive care medicine]]
[[Category:Causes of death]]
{{WH}}
{{WH}}
{{WS}}
{{WS}}

Latest revision as of 18:29, 3 March 2020

Ventricular fibrillation Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Ventricular Fibrillation from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

EKG examples

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Ventricular fibrillation medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Ventricular fibrillation medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Ventricular fibrillation medical therapy

CDC on Ventricular fibrillation medical therapy

Ventricular fibrillation medical therapy in the news

Blogs on Ventricular fibrillation medical therapy

Directions to Hospitals Treating Ventricular fibrillation

Risk calculators and risk factors for Ventricular fibrillation medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

In the event of cardiac arrest due to ventricular fibrillation, the immediate implementation of ACLS guidelines is indicated. When a sudden cardiac arrest occurs, immediate CPR is a vital link in the chain of survival. Another important link is early defibrillation, which has improved greatly with the widespread availability of AEDs. It often starts with analysing patient's heart rhythms with a manual defibrillator.

Medical Therapy

Defibrillation

Electric Defibrillator

The condition can often be reversed by the electric discharge of direct current from a defibrillator. Although a defibrillator is designed to correct the problem, and its effects can be dramatic, it is not always successful.

Implantable Electric Defibrillator

In patients at high risk of ventricular fibrillation, the use of an implantable cardioverter defibrillator has been shown to be beneficial.

Precordial Thump

If no defibrillator is available, a precordial thump can be delivered at the onset of VF for a small chance to regain cardiac function. However, research has shown that the precordial thump releases no more than 30 joules of energy. This is far less than the 200–360 J typically used to bring about normal sinus rhythm. Consequently, in the hospital setting, this treatment is not used.

Antiarrhythmic Agents

Antiarrhythmic agents like amiodarone or lidocaine can help, but, unlike atrial fibrillation, ventricular fibrillation rarely reverses spontaneously in large adult mammals. Drug therapy with antiarrhythmic agents in ventricular fibrillation does not replace defibrillation and is not the first priority, but is sometimes needed in cases where initial defibrillation attempts are not successful.

Medications that may be used include:

Contraindicated medications

Ventricular fibrillatioins is considered an absolute contraindication to the use of the following medications:

2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death[1]

Acute Management of Ventricular Fibrillation

Class I
" In patients with hemodynamically unstable VA that persist or recur after a maximal energy shock, intravenous amiodarone should be administered to attempt to achieve a stable rhythm after further defbrillation. (Level of Evidence: A)"
Class IIa
"In patients with symptomatic, non–lifethreatening VA, treatment with a beta blocker is reasonable. (Level of Evidence: C)"
Class IIb
"In patients with VT/VF storm in whom a beta blocker, other antiarrhythmic medications, and catheter ablation are ineffective, not tolerated, or not possible, cardiac sympathetic denervation may be reasonable.(Level of Evidence: C)"

Ventricular Fibrillation in Specific Conditions

Class I
"In patients with polymorphic VT or VF with ST-elevation MI, angiography with emergency revascularization is recommended. (Level of Evidence: B)"
Class IIa
"In patients with a witnessed cardiac arrest due to VF or polymorphic VT that is unresponsive to CPR, defbrillation, and vasopressor therapy, intravenous lidocaine can be benefcial.(Level of Evidence: B)"
"In patients with a recent MI who have VT/VF that repeatedly recurs despite direct current cardioversion and antiarrhythmic medications (VT/VF storm), an intravenous beta blocker can be useful.(Level of Evidence: B)"
Class III (No Benefit)
" In patients with refractory VF not related to torsades de pointes, administration of intravenous magnesium is not benefcial.(Level of Evidence: C)"
"In patients with incessant VT or VF, an ICD should not be implanted until suffcient control of the VA is achieved to prevent repeated ICD shocks. (Level of Evidence: C)"

References

  1. Al-Khatib, Sana M.; Stevenson, William G.; Ackerman, Michael J.; Bryant, William J.; Callans, David J.; Curtis, Anne B.; Deal, Barbara J.; Dickfeld, Timm; Field, Michael E.; Fonarow, Gregg C.; Gillis, Anne M.; Granger, Christopher B.; Hammill, Stephen C.; Hlatky, Mark A.; Joglar, José A.; Kay, G. Neal; Matlock, Daniel D.; Myerburg, Robert J.; Page, Richard L. (2018). "2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death". Circulation. 138 (13). doi:10.1161/CIR.0000000000000549. ISSN 0009-7322.

Template:WH Template:WS